Edited by Flávio Kapczinski, Clinical Hospital of Porto Alegre, Brazil, Eduard Vieta, University of Barcelona, Spain, Pedro V. S. Magalhães, Clinical Hospital of Porto Alegre, Brazil, and Michael Berk, Deakin University, Melbourne, Australia
Flávio Kapczinski is Professor of Psychiatry, Director of Research and Head of the Molecular Psychiatry Laboratory at the Hospital de Clínicas de Porto Alegre, Brazil. He is Consultant for the National Council of Scientific and Technological Development (CNPq). He has wide experience in clinical research, being lead investigator in several clinical trials, some funded by the Stanley Medical Research Institute and Brain & Behavioral Foundation. His work identified biological underpinnings of the decline in cognition and physical health among patients with bipolar disorder. He has published over 302 peer-reviewed papers and has 4700 citations with an H-index of 35. Recently his research has focused on neurotoxicity mechanisms linked to mood episodes and the use of a systemic toxicity index, supporting the notion that bipolar disorder is a systemic illness, approximating psychiatry to other fields of medicine. He currently coordinates the Brazilian National Institute of Translational Medicine.
Eduard Vieta is Professor of Psychiatry, Head of Department and Director of the Bipolar Disorders Program of the Hospital Clinic at the University of Barcelona, Spain. He is Director of the Bipolar Research Program at the Spanish Research Network on Mental Diseases (CIBERSAM) funded by the Spanish Ministry of Science and Innovation. His research focuses on the neurobiology, epidemiology and treatment of bipolar disorder. He received the 2007 Aristotle Award, the 2005 Mogens Schou Award and the 2012 Colvin Prize on Outstanding Achievement in Mood Disorders Research by the Brain and Behaviour Research Foundation. Having made significant contributions to many published bipolar disorder treatment guidelines he has authored over 500 articles, 200 chapters and 27 books. His H index is 70 with over 18000 citations. He is on editorial boards of many international scientific journals. He has served as Invited Professor at Harvard University and Neuroscience Scientific Advisor to the European Presidency.
Pedro V. S. Magalhães is Professor of Psychiatry at the Federal University of Rio Grande do Sul. He also holds the posts of Associate Editor at RBP Psychiatry and Field Editor for Literature Reviews at Acta Psychiatrica Scandinavica. The main lines of research he has developed and continues in recent years is the translational medicine and epidemiology of mood disorders and the development of novel treatment approaches to these disorders, including medications that oxidative stress and inflammation pathways.
Michael Berk is Professor and Alfred Deakin Chair of Psychiatry at Deakin University and Honorary Professorial Research Fellow in the Department of Psychiatry at the Florey Institute for Neuroscience and Mental Health and Orygen Youth Health at Melbourne University. He has published over 450 papers on mood disorders, his greatest contribution being the discovery and implementation of novel therapies. He has published 25 self-initiated randomised controlled trials, pioneering randomised placebo controlled trials of N-acetyl cysteine in depression and bipolar disorder maintenance treatment, establishing an entirely new treatment and implicating a novel mechanism of disease. He was founding editor of the Journal of Depression and Anxiety and has been involved with 12 other journals. He holds grants from the National Institutes of Health (US), Simon Autism Foundation, NHMRC CRE and Stanley Medical Research Institute and is lead investigator on a successful Collaborative Research Centre application.
Robert M. Post, Bipolar Collaborative Network, Suite 201-B, Bethesda, MD, USA
Ralph W. Kupka, Altrecht Institute for Mental Health Care and University Medical Center Utrecht, Utrecht, The Netherlands
Manon H. J. Hillegers, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, The Netherlands
Jan Scott, Academic Psychiatry, Wolfson Unit, Camous for Vitality & Ageing, Newcastle upon Tyne, UK
Iria Grande, Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
Luis Guilherme Streb, Bipolar Disorder Program and Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, National Institute for Translational Medicine, Porto Alegre, Brazil
Flávio Kapczinski, Bipolar Disorder Program and Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, National Institute for Translational Medicine, Porto Alegre, Brazil
Gabriel R. Fries, Laboratory of Molecular Psychiatry, Centro de Pesquisas Experimentais, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Pedro V. S. Magalhães, Molecular Psychiatry Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Michael Berk, NHMRC Senior Principal Research Fellow, Alfred Deakin Professor of Psychiatry, School of Medicine, Deakin University, Director, IMPACT Strategic Research Centre (Innovation in Mental and Physical Health and Clinical Treatment), Professorial Research Fellow, The Florey Institute of Neuroscience and Mental Health, Orygen Research Centre and the Department of Psychiatry, University of Melbourne, Melbourne, Australia
Adriane R. Rosa, PharmD, PhD, Professor of Pharmacology, Universidade Federal do Rio Grande do Sul (UFRGS), Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Clarissa S. Gama, Molecular Psychiatry Laboratory, Hospital de Clínicas de Porto Alegre/CPE, Porto Alegre, Brazil
Eduard Vieta, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Anabel Martínez-Arán, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Caterina del Mar Bonnin, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Carla Torrent, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Brisa Solé, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Imma Torres, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Esther Jiménez, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Sergio A. Strejilevich, Bipolar Disorders Program, Department of Psychiatry, Favaloro Foundation Neuroscience Institute, Buenos Aires, Argentina
Diego J. Martino, Bipolar Disorders Program, Department of Psychiatry, Favaloro Foundation Neuroscience Institute, Buenos Aires, Argentina
Gustavo H. Vázquez, Department of Neuroscience, University of Palermo, Buenos Aires, Argentina
Xenia Gonda, Department of Clinical and Theoretical Mental Health, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Benicio N. Frey, Associate Professor, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
Luciano Minuzzi, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
Bartholomeus C.M. Haarman, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
Roberto B. Sassi, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
Aroldo A. Dargél, Laboratory of Molecular Psychiatry, INCT Translational Medicine, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre (RS), Brazil
Marion Leboyer, Université Paris-Est, INSERM U955, Psychiatrie Génétique – Eq. 15, F-94000, Créteil, France
Joana Bücker, Laboratory of Molecular Psychiatry and Bipolar Disorders Program and INCT Translational Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Marcia Kauer-Sant'Anna, Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Lakshmi N. Yatham, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
Anusha Baskaran, Centre for Neuroscience Studies, Queen 's University; Providence Care, Mental Health Services, Kingston, ON, Canada
Benjamin I. Goldstein, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Roger McIntyre, UHN - Toronto Western Hospital, Toronto, ON, Canada
Romain Icick, CSAPA Espace Murger, Service de Psychiatrie d'Adultes, Groupe Hospitalier Saint-Louis - Lariboisiere - Fernand Widal, Assistance Publique - Hopitaux de Paris, Paris, France
Frank Bellivier, INSERM U797, Pole de Psychiatrie, CHU de Créteil, Hôpital Henri Mondor & Paris 12 University, Créteil, France
Janusz K. Rybakowski, Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
Vicent Balanzá-Martínez, Department of Medicine, University of Valencia, Valencia, Spain
María Lacruz, Hospital Francesc de Borja, Valencia, Spain
Rafael Tabarés-Seisdedos, Department of Medicine, University of Valencia, Valencia, Spain
Aline André Rodrigues, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
Maurício Kunz, Laboratório de Psiquiatria Molecular, Centro de Pesquisas, Hospital de Clínicas de Porto Alegre, Programa de Pós-Graduação em Medicina Psiquiatria, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
María Reinares, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
Francesc Colom, IDIBAPS, Bipolar Disorders Program, Hospital Clínic, University of Barcelona, Barcelona, Spain
